Atlas Trials

An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab

Clinical trial NCT05394792 · COMPLETED

Trial details

NCT number
NCT05394792
Sponsor
AbbVie
Status
COMPLETED
Study type
OBSERVATIONAL
Atopic Dermatitis
Start date
2022-06-01
Primary completion
2024-08-15
Enrollment
111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.